Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Profit After Tax of -$36.8 million for Q3 2025, down 46.04% year-over-year from -$68.1 million in Q3 2024, and down 16.24% quarter-over-quarter from -$31.6 million in Q2 2025.
Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$36.8 million for Q3 2025.
- In Q3 2025, Profit After Tax fell 46.04% year-over-year to -$36.8 million; the TTM figure through Sep 2025 stood at -$126.4 million (down 88.26% YoY), while the FY2024 annual figure was -$85.0 million, down 94.95% from the prior year.
- Profit After Tax for Q3 2025 stood at -$36.8 million, down from -$31.6 million in the prior quarter.
- The five-year high for Profit After Tax was -$4.9 million in Q1 2022, with the low at -$36.8 million in Q3 2025.
- The 5-year median for Profit After Tax is -$16.9 million (2021), against an average of -$17.2 million.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax jumped 72.09% in 2022, then plunged 168.59% in 2024.
- Dianthus Therapeutics' Profit After Tax stood at -$19.3 million in 2021, then soared by 47.53% to -$10.1 million in 2022, then decreased by 4.67% to -$10.6 million in 2023, then slumped by 168.59% to -$28.5 million in 2024, then retreated by 29.13% to -$36.8 million in 2025.
- Business Quant data shows DNTH's Profit After Tax at -$36.8 million in Q3 2025, -$31.6 million in Q2 2025, and -$29.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -36.77 Mn |
| Jun 30, 2025 | -31.63 Mn |
| Mar 31, 2025 | -29.51 Mn |
| Dec 31, 2024 | -28.47 Mn |
| Sep 30, 2024 | -25.17 Mn |
| Jun 30, 2024 | -17.61 Mn |
| Mar 31, 2024 | -13.75 Mn |
| Dec 31, 2023 | -10.60 Mn |
| Sep 30, 2023 | -14.76 Mn |
| Jun 30, 2023 | -11.14 Mn |
| Mar 31, 2023 | -7.09 Mn |
| Dec 31, 2022 | -10.13 Mn |
| Sep 30, 2022 | -7.93 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Mar 31, 2022 | -4.88 Mn |
| Dec 31, 2021 | -19.30 Mn |
| Sep 30, 2021 | -17.43 Mn |
| Jun 30, 2021 | -16.94 Mn |
| Mar 31, 2021 | -17.49 Mn |
| Dec 31, 2020 | -18.20 Mn |